PIVKA – II Test at Ayzal Lab

PIVKA – II at Ayzal Lab

Proteins Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), also known as des-gamma-carboxy prothrombin (DCP), is a highly specialized serum biomarker used primarily in clinical oncology and hepatology. Ayzal Lab, a premier diagnostic facility located in Lahore, Pakistan, provides this advanced chemiluminescent microparticle immunoassay (CMIA) to assist clinicians in the early detection, monitoring, and management of hepatocellular carcinoma (HCC). This laboratory test measures an abnormal, non-functional form of prothrombin that accumulates in the blood when there is a deficiency of vitamin K or when malignant hepatocytes lose their ability to properly carboxylate clotting factors.

The liver is responsible for synthesizing essential coagulation factors, including prothrombin (Factor II). This synthesis relies on a vitamin K-dependent carboxylase enzyme to convert specific glutamic acid residues into gamma-carboxyglutamic acid. In hepatocellular carcinoma, the neoplastic liver cells exhibit a dysfunctional carboxylation pathway, leading to the secretion of uncarboxylated prothrombin (PIVKA-II) into the bloodstream. Because PIVKA-II levels rise significantly in patients with liver malignancies, this test serves as an invaluable diagnostic tool, often demonstrating superior sensitivity and specificity compared to traditional biomarkers like Alpha-Fetoprotein (AFP) for specific patient cohorts.

At Ayzal Lab in Lahore, Pakistan, the PIVKA-II test is performed utilizing state-of-the-art automated immunoassay platforms. This ensures high analytical sensitivity, precision, and rapid turnaround times. Evaluating PIVKA-II is clinically vital for patients with chronic liver diseases, including hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, and liver cirrhosis, who are at an elevated risk of developing primary liver cancer. By measuring this biomarker, healthcare providers can detect neoplastic changes at an early, potentially resectable stage, significantly improving patient prognosis and survival rates.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of your PIVKA-II test results at Ayzal Lab, patients should adhere to the following preparation guidelines:

• Fasting Requirements: While a strict fast is not universally mandatory for PIVKA-II, a fasting period of 8 to 12 hours is highly recommended to minimize lipemia in the serum sample, which can interfere with optical immunoassay measurements.
• Medication Disclosure: Patients must inform the laboratory staff and their referring physician of all medications they are currently taking. Specifically, oral anticoagulants like Warfarin (Coumadin) directly inhibit vitamin K epoxide reductase, which artificially elevates PIVKA-II levels.
• Vitamin K Supplements: Inform the clinical team if you have recently received vitamin K injections or oral supplements, as these can artificially suppress PIVKA-II levels, potentially masking underlying pathology.
• Hydration: Drink plenty of water before the test to ensure adequate hydration, which facilitates easier venous access during sample collection.

During the Procedure

The PIVKA-II test is a standard venipuncture procedure conducted by highly trained phlebotomists at Ayzal Lab. The process is quick, safe, and minimally invasive:

• Patient Positioning: The patient is comfortably seated in a specialized phlebotomy chair, and the arm is extended and supported.
• Site Selection and Cleansing: The phlebotomist identifies a suitable vein, typically in the antecubital fossa (the crook of the elbow), and cleanses the skin thoroughly with an antiseptic alcohol swab to prevent contamination.
• Venipuncture: A sterile, single-use needle is gently inserted into the vein. A vacuum collection tube (typically a gold-top serum separator tube or red-top tube) is attached to collect the required volume of blood (approximately 3 to 5 mL).
• Post-Collection Care: Once the sample is collected, the needle is withdrawn, and a sterile cotton ball or gauze is applied to the puncture site with gentle pressure to stop any minor bleeding. A bandage is then applied.
• Sample Processing: The blood sample is allowed to clot naturally before being centrifuged at high speeds to separate the serum. The serum is then analyzed using advanced automated immunoassay technology.

When is a PIVKA – II Test Performed?

Screening for Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma is one of the most common primary liver malignancies globally. Physicians frequently order the PIVKA-II test at Ayzal Lab to screen high-risk populations, particularly individuals diagnosed with chronic hepatitis B, hepatitis C, or non-alcoholic fatty liver disease (NAFLD). Because early-stage HCC is often asymptomatic, routine screening with PIVKA-II helps identify neoplastic transformations long before physical symptoms or structural abnormalities appear on standard imaging studies.

Surveillance of Liver Cirrhosis Patients

Cirrhosis represents the end-stage of progressive liver fibrosis and is a major predisposing factor for primary liver cancer. Patients with established liver cirrhosis undergo regular surveillance protocols. Clinicians request the PIVKA-II test alongside abdominal ultrasounds every six months to monitor these patients. A sudden elevation in PIVKA-II levels serves as a critical clinical indicator, prompting immediate high-resolution contrast-enhanced imaging (CT or MRI) to locate potential dysplastic nodules or early malignant lesions.

Monitoring Therapeutic Response

For patients undergoing treatment for hepatocellular carcinoma—such as surgical resection, liver transplantation, transarterial chemoembolization (TACE), or systemic targeted therapies—the PIVKA-II test is used as a therapeutic monitor. A successful intervention should result in a rapid, significant decline in serum PIVKA-II levels. Conversely, persistently high or rising levels post-treatment indicate incomplete tumor eradication or refractory disease, guiding oncologists to adjust the therapeutic strategy.

Detecting Tumor Recurrence

Following successful treatment of liver cancer, patients require long-term monitoring to detect potential disease recurrence. Ayzal Lab performs serial PIVKA-II testing during follow-up consultations. Because PIVKA-II has a relatively short half-life in circulation, it serves as an exceptionally sensitive marker for early recurrence, often rising months before recurrent tumors become visible on conventional radiological scans, allowing for timely secondary interventions.

Differentiating Malignancy from Benign Liver Disease

Distinguishing between benign regenerative nodules in a cirrhotic liver and true hepatocellular carcinoma can be clinically challenging. While alpha-fetoprotein (AFP) can be elevated in benign inflammatory conditions like acute hepatitis flare-ups, PIVKA-II is highly specific to neoplastic processes. Physicians utilize the PIVKA-II test to help differentiate malignant lesions from benign hepatic conditions, reducing diagnostic uncertainty and preventing unnecessary invasive liver biopsies.

What Does a PIVKA – II Test Detect?

The PIVKA-II test at Ayzal Lab is highly sensitive to specific biochemical alterations associated with liver pathology. It detects and assists in evaluating:

• Elevated levels of des-gamma-carboxy prothrombin (DCP) in circulation.
• Early-stage hepatocellular carcinoma in patients with low or normal AFP levels.
• Vitamin K deficiency states, which impair normal coagulation factor carboxylation.
• The biochemical impact of warfarin and other vitamin K antagonists on clotting factor synthesis.
• Subclinical hepatic dysfunction affecting protein synthesis pathways.
• The presence of microvascular invasion in diagnosed liver tumors, as high PIVKA-II levels correlate with aggressive tumor biology.
• Tumor burden and tumor size, with larger lesions generally producing higher concentrations of the biomarker.
• Response to local ablative therapies, such as radiofrequency ablation (RFA).
• Early recurrence of primary liver tumors during post-treatment surveillance.
• Congenital or acquired defects in the gamma-glutamyl carboxylase enzyme system.

Turnaround Time and Report Access at Ayzal Lab

At Ayzal Lab, we understand that timely diagnostic results are crucial for effective clinical decision-making, particularly in oncology. The PIVKA-II test is processed using fully automated, high-throughput analyzers to ensure both speed and accuracy. Reports are typically completed and verified by our consultant pathologist within 24 to 48 hours of sample collection. Patients and referring physicians can conveniently access, download, and print reports online through the secure Ayzal Lab patient portal, or receive them directly via WhatsApp and email, eliminating the need for unnecessary travel back to the diagnostic center.

PIVKA – II Findings Overview

The following table outlines the clinical interpretation of PIVKA-II test results:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Serum PIVKA-II Concentration	Less than 40 mAU/mL (may vary slightly by assay platform)	Elevated levels (≥ 40 mAU/mL), highly suggestive of hepatocellular carcinoma or severe vitamin K deficiency.
Vitamin K Status	Sufficient vitamin K levels leading to fully carboxylated prothrombin	Deficiency states resulting in elevated uncarboxylated prothrombin (PIVKA-II) in circulation.
Anticoagulant Therapy Effect	No active vitamin K antagonist therapy	Markedly elevated PIVKA-II levels due to therapeutic Warfarin/coumarin administration.
Hepatic Synthetic Function	Normal carboxylation of coagulation factors in hepatocytes	Impaired carboxylation due to parenchymal liver disease or neoplastic transformation.
Tumor Biology Correlation	No active hepatic malignancy detected	Very high levels (> 400 mAU/mL) strongly correlate with portal vein invasion and aggressive tumor phenotypes.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Ayzal Lab for PIVKA – II?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists, clinical biochemists, and skilled phlebotomists dedicated to diagnostic excellence.
• Patient-Focused Care: We prioritize patient comfort, safety, and confidentiality at every stage of the diagnostic journey.
• Quality Diagnostic Services: Ayzal Lab adheres to strict internal and external quality control protocols to ensure highly reproducible and accurate test results.
• Professional Reporting: All reports are verified by consultant pathologists and include comprehensive reference ranges for clear clinical interpretation.
• Modern Diagnostic Approach: We utilize advanced chemiluminescent immunoassay technology to deliver precise biomarker quantification.
• Comfortable Environment: Our modern collection centers in Lahore are designed to provide a stress-free and hygienic experience for all patients.
• Convenient Location: Easily accessible facilities across Lahore make it simple for patients to undergo testing without long commutes.
• Commitment to Accurate Diagnosis: We understand the critical nature of tumor marker testing and are committed to delivering reliable results that physicians trust.